Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Status: RecruitingPhase: Phase 1Diagnosis: GYN: Ovarian, Fallopian, Peritoneal CancerNCT ID: NCT01623349
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 12-159
This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational combination of drugs. Phase I studies also try to define the appropriate dose of the investigational combination to use for further studies. "Investigational" means that the combination of these drugs is still being studied and that research doctors are trying to find out more about it. It also means that the FDA has not approved either of these drugs nor the combination of being tested for use in patients, including people with your type of cancer. BKM120, BYL719 and olaparib are drugs that may stop cancer cells from growing abnormally. These drugs when combined in laboratory experiments with animals, have demonstrated anti-cancer activity. Information from these other research studies suggests that the following agents BKM120, BYL719 and olaparib, may help to shrink tumor cells in the types of cancers being studied in this research study. In this research study, the investigators are looking for the highest dose that can be given safely and also to see if the combination of BKM120 or BYL719 and olaparib is effective in treating your type of cancer.
Conducting Institutions: Dana-Farber Cancer Institute, Beth-Israel Deaconess Medical Center, Massachusetts General Hospital
Overall PI: Ursula Matulonis, MD,
Dana-Farber Cancer Institute
Site-responsible Investigators: Gerburg Wulf, MD,
Beth Israel Deaconess Medical CenterMichael Birrer, MD, PhD,
Massachusetts General Hospital
Contacts: Dana-Farber Cancer Institute:
Christin Whalen, 617-582-7738,
firstname.lastname@example.orgMassachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100Massachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100